Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma

PUBT · 2d ago
Molecular Partners doses first patients in Phase 2 MP0317 combo trial for cholangiocarcinoma
  • Molecular Partners began dosing in a randomized Phase 2 TACTIC trial of MP0317 with frontline chemoimmunotherapy in advanced cholangiocarcinoma.
  • France-based study targets 75 patients in a 2-to-1 split, comparing MP0317 combination therapy against standard-of-care alone.
  • Nine sites are recruiting; data update targeted for 2027, trial completion expected in 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607160100PRIMZONEFULLFEED9762978) on July 16, 2026, and is solely responsible for the information contained therein.